For the past thirty years, Europe has built one of the world’s most respected medicine regulatory systems. The centralised authorisation process has enabled groundbreaking treatments to reach millions of patients while maintaining the rigorous standards of quality, safety and efficacy that underpin public confidence in healthcare.
But as Europe marks this milestone, the industry’s priorities are evolving.
Scientific innovation continues at an extraordinary pace. Cell and gene therapies, personalised
medicines and next-generation vaccines are transforming what is possible for patients.
Yet the events of recent years – from the COVID-19 pandemic to geopolitical instability and ongoing medicine shortages – have highlighted an equally important question: what value does innovation create if patients cannot reliably access the medicines they need?
This is the challenge shaping the next chapter of the European pharmaceutical landscape. Regulatory excellence is no longer defined solely by bringing innovative medicines to market. Increasingly, it will also be measured by an organisation’s ability to ensure those medicines remain consistently available.
Thirty Years of Progress
The introduction of the EU’s centralised authorisation procedure in 1995 transformed the way innovative medicines reached patients across Europe. Rather than navigating separate approval processes in individual countries, companies could obtain a single marketing authorisation following scientific assessment by the European Medicines Agency (EMA), providing access across EU member states.
Over the past three decades, this framework has supported the approval of almost 2,000 centrally authorised medicines, including treatments for cancer, rare diseases, HIV, diabetes, multiple sclerosis and hepatitis C. It has also enabled the development of hundreds of medicines for children and rare diseases, advanced therapies such as gene and cell therapies, and vaccines protecting against both longstanding and emerging infectious diseases.
More importantly, the system has helped create an environment where scientific innovation can flourish. Breakthroughs that once seemed unimaginable – including CAR-T therapies, personalised cancer treatments and gene therapies capable of addressing inherited diseases at their source – are now becoming part of routine clinical practice.
For pharmaceutical companies, however, scientific innovation has become only one part of the equation.
As therapies become more sophisticated, so too do the regulatory, manufacturing and supply chain requirements needed to bring them successfully to patients.
A New Definition of Pharmaceutical Excellence
For many years, regulatory success was largely measured by one outcome: securing timely approval for safe and effective medicines. That definition is changing. Today, regulators, healthcare systems and patients are increasingly asking a different question: can companies continue to supply those medicines consistently once they reach the market?
Medicine shortages have become a persistent challenge across Europe. While individual shortages may stem from manufacturing issues, quality concerns, unexpected increases in demand, shortages of raw materials or wider geopolitical pressures, the underlying lesson is clear. Modern pharmaceutical supply chains have become highly interconnected, and with that interconnectedness comes greater vulnerability.
This represents more than an operational challenge. It signals a broader shift in regulatory thinking.
Supply resilience is becoming an integral part of how regulators assess the pharmaceutical ecosystem. The ability to anticipate disruption, diversify manufacturing, strengthen supplier networks and respond rapidly to emerging risks is increasingly viewed as essential to protecting patient access.
In other words, regulatory excellence is expanding beyond compliance to encompass resilience.
Europe’s Regulatory Response Signals a Strategic Shift
Several recent European initiatives illustrate this evolution. The proposed Critical Medicines Act seeks to strengthen European manufacturing capacity, reduce strategic dependencies and encourage greater investment in resilient supply chains for medicines considered essential to public health.
At the same time, proposed reforms to EU pharmaceutical legislation place greater emphasis on shortage prevention, earlier risk identification and enhanced collaboration between manufacturers and regulators.
The European Shortages Monitoring Platform is designed to improve visibility of medicine availability across Member States, while the Union List of Critical Medicines helps focus attention on products where supply disruptions could have the greatest impact on patients.
Viewed individually, these initiatives address different aspects of pharmaceutical policy. But viewed together, they reveal something much more significant. Europe is moving from regulating medicines alone to strengthening the resilience of the systems that deliver them.
This represents one of the most important shifts in pharmaceutical regulation since the creation of the centralised authorisation process itself.
What This Means for Pharmaceutical Leaders
The implications extend well beyond regulatory affairs. Supply chain resilience is rapidly becoming a strategic capability rather than simply an operational function. Organisations that can demonstrate robust manufacturing networks, diversified sourcing strategies and proactive risk management are likely to be better positioned to meet evolving regulatory expectations, while strengthening relationships with healthcare systems and patients.
Equally, the traditional boundaries between regulatory affairs, quality, manufacturing and supply chain management are beginning to blur. Decisions in one area increasingly influence outcomes in another, requiring far closer collaboration across functions than has historically been the case. Ultimately, resilience can no longer be treated as a contingency plan. It must become part of product strategy from the earliest stages of development.
Companies that embed regulatory planning, manufacturing strategy and supply resilience into a single integrated approach will be better equipped to navigate future change than those that continue to manage these disciplines independently.
Looking Ahead
Europe’s commitment to scientific innovation remains clear. The region continues to support the development of advanced therapies, medicines for rare diseases and technologies capable of transforming patient care.
But the next decade is unlikely to be defined solely by scientific breakthroughs. It will be defined by whether healthcare systems can ensure those breakthroughs reach patients consistently, reliably and equitably.
The organisations that succeed will not necessarily be those with the largest research pipelines. They will be those capable of combining scientific innovation with operational resilience, regulatory excellence and long-term supply security.
Innovation and resilience are no longer competing priorities. Together, they represent the future of European medicines.
Acorn Regulatory’s Perspective
At Acorn Regulatory, we believe the pharmaceutical industry is entering a new era – one in which regulatory strategy, quality, manufacturing and supply resilience can no longer be considered in isolation.
Helping organisations navigate this increasingly interconnected environment requires more than keeping pace with regulatory change. It requires understanding how evolving legislation, operational capability and commercial strategy combine to influence long-term success.
As we approach our own 25-year milestone, we’re proud to continue supporting pharmaceutical and life sciences organisations as they adapt to the changing regulatory landscape and prepare for the next generation of innovation.
Because the future of European medicines will not be defined simply by the therapies we develop. It will be defined by our ability to ensure patients can depend on them.
Looking for support navigating Europe’s evolving pharmaceutical regulatory landscape?
Whether you’re preparing for new regulatory requirements, strengthening compliance processes or planning for future market access, Acorn’s experts can help you stay ahead of change.
Contact Acorn Regulatory to discuss your regulatory affairs, compliance and pharmaceutical strategy challenges, or follow us for more insights on the future of European medicines.
